New Strategies in Pediatric Gliomas: Molecular Advances in Pediatric Low-Grade Gliomas as a Model

Eric Raabe1, Mark W. Kieran2, and Kenneth J. Cohen1

Abstract

Pediatric low-grade gliomas (pLGG) account for more brain tumors in children than any other histologic subtype. While surgery, chemotherapy and radiation remain the mainstay of upfront treatment, recent advances in molecular interrogation of pLGG have shown a small number of recurring genetic mutations in these tumors that might be exploited therapeutically. Notable findings include abnormalities in the RAS/MAP kinase pathway such as NF-1 loss or BRAF activation and mTOR activation. Recent identification of activating re-arrangements in c-MYB and MYBL1 in pediatric diffuse astrocytoma also provide candidates for therapeutic intervention. Targeting these molecularly identified pathways may allow for improved outcomes for patients as pediatric oncology moves into the era of biology-driven medicine.

Background

Pediatric gliomas include multiple histologies including astrocytomas, ependymomas, and oligodendrogliomas. Pediatric low-grade gliomas (pLGG) are the most common pediatric brain tumors, and this review will focus on the emerging translational science related to these tumor types.

Pediatric astrocytic tumors are currently divided by the World Health Organization (WHO) into numerous subtypes (Table 1). pLGG include WHO grade I and II tumors with pilocytic astrocytomas predominating. Although most pLGG carry a favorable prognosis, a significant minority are more aggressive (1). Surgical resection can be curative, but this is often not feasible due to the tendency of these tumors to present in midline locations including the diencephalon and brain stem (2). Radiation therapy can be used in the adjuvant setting for recurrent or progressive tumors. Unfortunately, there can be significant long-term morbidity including impaired cognition, vasculopathy, endocrinopathies, and secondary tumors (3). Chemotherapy, which was presumed to be less efficacious in the treatment of LGG given the relatively slow growth rate of these tumors, was initially reluctantly used when surgical and radiation options had been exhausted. However, responses were seen in both the upfront and recurrence setting, generating interest in the use of chemotherapy to avoid, or delay, radiation therapy. Numerous regimens have been developed including carboplatin/vincristine (4, 5), TPCV (thioguanine/procarbazine/CCNU, vincristine; ref. 6), carboplatin alone (7), oral temozolomide (8), vinblastine (9), cisplatin/etoposide (10), and others. In general, regardless of regimen, a minority of children will have a measurable reduction in the size of the tumor, many will have stable disease, and the remainder will progress during or after completion of treatment. Progression-free survival (PFS)
Diffuse low-grade astrocytomas have activating alterations of the MYB or MYBL1 transcription factors (22, 23). These tumors also have MAP kinase activation equivalent to that observed in BRAF-driven tumors, suggesting that MAP kinase signaling may be a common driver pathway in pLGG. High-level activation of the MAP kinase pathway is associated with oncogene-induced senescence in many neoplasms, and the most aggressive pLGGs have deletion or silencing of the p16INK4a locus, allowing them to bypass this antitumor mechanism (24–26).

The presence of characteristic mutations provides a rational target for therapy. For example, the finding of BRAFV600E in a subset of pLGGs led to the hypothesis that some of the pharmaceuticals designed to inhibit this mutation in melanoma might be active against these tumors (27, 28). Dabrafenib has improved brain penetration and has shown activity against melanoma brain metastases (29, 30). A multinational pediatric phase I/II study of dabrafenib in patients with known BRAFV600E tumors is currently underway (NCT01677741). Recent studies have shown that current BRAF inhibitors are designed specifically for the BRAFV600E mutation and can cause paradoxical activation of other BRAF-activating mutations (such as the BRAF/KIAA1549 fusion protein; ref. 31). Adding further complexity, there are several different BRAF/KIAA1549 fusions, and several BRAF translocations identified that do not involve KIAA1549 (32).

The advent of improved MAP kinase pathway inhibitors (MEK inhibitors) has led to successful preclinical testing in murine models of pilocytic astrocytomas and initiation of a trial of one such inhibitor, selumetinib, in patients with LGG (NCT01089101; ref. 33). Downstream inhibition of the RAS/BRAF/MEK pathway is attractive because it is possible that this class of drug could be used regardless of the upstream mutation leading to pathway activation. However, RAS and BRAF are capable of signaling through other downstream effectors (such as the mTOR pathway), and MEK inhibitors may not target these other pathways effectively (34–36). In preclinical testing, one pilocytic astrocytoma xenograft harboring the BRAFV600E mutation responded to MEK inhibition, whereas another that did not have the mutation was resistant (33).

### On The Horizon

**Targeting the RAS/MAP kinase pathway**

Nearly all pLGGs have alterations in the RAS/MAP kinase pathway (Fig. 1; refs. 14–16). Constitutive activation of this pathway can be due to loss of neurofibromin (NF-1), a RAS GTPase-activating protein (17, 18). In non–NF-1-associated LGG, the most common alteration is a fusion and tandem duplication of BRAF with KIAA1549, a protein of unknown function (19). This fusion deletes the regulatory domain of BRAF and deletes most of KIAA1549, leaving a rump of KIAA1549 and a constitutively active BRAF (14–16). A smaller percentage of LGG harbor the BRAFV600E mutation (20) that is a hallmark of cutaneous melanoma (21). Another subset harbors fibroblast growth factor receptor (FGFR) alterations leading to constitutive activation of the mitogen-activated protein (MAP) kinase and mTOR pathways (22). Interestingly, a group of predominantly diffuse low-grade astrocytomas have activating alterations of the MYB or MYBL1 transcription factors (22, 23). These tumors also have MAP kinase activation equivalent to that observed in BRAF-driven tumors, suggesting that MAP kinase signaling may be a common driver pathway in pLGG. High-level activation of the MAP kinase pathway is associated with oncogene-induced senescence in many neoplasms, and the most aggressive pLGGs have deletion or silencing of the p16INK4a locus, allowing them to bypass this antitumor mechanism (24–26).

The presence of characteristic mutations provides a rational target for therapy. For example, the finding of BRAFV600E in a subset of pLGGs led to the hypothesis that some of the pharmaceuticals designed to inhibit this mutation in melanoma might be active against these tumors (27, 28). Dabrafenib has improved brain penetration and has shown activity against melanoma brain metastases (29, 30). A multinational pediatric phase I/II study of dabrafenib in patients with known BRAFV600E tumors is currently underway (NCT01677741). Recent studies have shown that current BRAF inhibitors are designed specifically for the BRAFV600E mutation and can cause paradoxical activation of other BRAF-activating mutations (such as the BRAF/KIAA1549 fusion protein; ref. 31). Adding further complexity, there are several different BRAF/KIAA1549 fusions, and several BRAF translocations identified that do not involve KIAA1549 (32).

The advent of improved MAP kinase pathway inhibitors (MEK inhibitors) has led to successful preclinical testing in murine models of pilocytic astrocytomas and initiation of a trial of one such inhibitor, selumetinib, in patients with LGG (NCT01089101; ref. 33). Downstream inhibition of the RAS/BRAF/MEK pathway is attractive because it is possible that this class of drug could be used regardless of the upstream mutation leading to pathway activation. However, RAS and BRAF are capable of signaling through other downstream effectors (such as the mTOR pathway), and MEK inhibitors may not target these other pathways effectively (34–36). In preclinical testing, one pilocytic astrocytoma xenograft harboring the BRAFV600E mutation responded to MEK inhibition, whereas another that did not have the mutation was resistant (33).

### mTOR pathway inhibition

Several recent studies have shown that the most aggressive and refractory pLGGs have increased activation of the mTOR pathway (37, 38). The success of the rapalog everolimus in treating SEGAs associated with tuberous sclerosis proved that this drug can shrink mTOR-driven tumors (12, 13), suggesting that it might have activity in other pLGG. A trial of everolimus in refractory/recurrent pLGG has completed enrollment (NCT00782626), and a second phase II trial targeting larger numbers of patients will soon be opening (NCT01734512). A separate study of everolimus in refractory/recurrent pLGG has completed enrollment (NCT00782626), and a second phase II trial targeting larger numbers of patients will soon be opening (NCT01734512). A separate study of everolimus in refractory/recurrent pLGG has completed enrollment (NCT00782626), and a separate study of everolimus in refractory/recurrent pLGG has completed enrollment (NCT00782626).

A series of 19 children treated with erlotinib showed prolonged stable disease in 2 children with NF-1 (39). It will be
important to determine whether increased TORC1 or TORC2 expression correlates with response to mTOR inhibitors, as these rapalogs are likely to primarily inhibit TORC1 (40). New dual TORC1/TORC2 targeting agents such as TORC kinase inhibitors may also be promising drugs for treatment of aggressive LGG.

**MYB and MYBL1 inhibition**

In low-grade fibrillary astrocytomas (WHO grade II) and a percentage of pilocytic astrocytomas, genomic rearrangements remove the regulatory domain of c-MYB and the closely related MYBL1 transcription factors (22, 23). These rearrangements leave the transactivating domain constitutively active (22, 23). The overactivation of c-MYB is a known oncogene in leukemia (41). Recently, new inhibitors of c-MYB have been developed, suggesting that these may be eventually deployed in MYB-rearranged pLGG (42).

**Anti-angiogenic therapy**

The intense expression of vascular growth factors in pilocytic astrocytoma suggests that these tumors may be dependent on neovascularization for their continued growth (43). Targeting these abnormal blood vessels with the VEGF inhibitor bevacizumab in conjunction with irinotecan led to radiologic and clinical responses in small numbers of children (44). Bevacizumab monotherapy has also been shown to lead to tumor regression and disease stability in patients with LGG (45).

**Immunomodulatory therapy**

The presence of characteristic mutations in pLGG that are not present in other cells in the body raises the possibility of targeting these abnormal peptides. One way that the immune system can be vectored to pLGG is with the immunomodulatory drug lenalidomide. In addition
to its ability to alter the immune milieu, lenalidomide has anti-angiogenic and direct antitumor effects (46). A phase I study of lenalidomide in patients with refractory/recurrent pediatric brain tumors found that patients with LGG were most likely to show cessation of tumor progression (46). A phase II study comparing 2 dose levels of lenalidomide to determine whether there is improved response with higher doses (NCT01553149) is ongoing.

A trial is underway investigating if vaccination with glioma-associated antigens along with concurrent administration of the immunostimulant poly-ICLC (polynonucleotide-polyacrylate acid stabilized by lysine and carboxymethylcellulose) can activate the immune system to attack refractory/recurrent LGG (NCT01130077). Poly ICLC is an immunomodulatory agent that promotes infiltration of T cells into tumors (47, 48). A phase II study of poly-ICLC alone in LGG is currently underway as well (NCT01188096).

**Rational for combination therapy in pLGGs**

Combination chemotherapy has been adapted to pLGGs not amenable to surgical resection (49). Activity of combination chemotherapy in LGGs remains controversial because of the number of single-agent therapies (see above) have shown results similar to single-agent therapy. However, there have not been controlled randomized trials comparing single versus multagent therapy in pLGGs. When considering why pLGGs may be effectively treated by single-agent therapy, it is important to recall the limited malignant capacity of these tumors. Radiation therapy for most pLGGs could be considered optimal single-agent treatment based on its ability to stabilize tumor growth. The predominance of mutations along the single RAS/RAF/MEK pathway in the absence of other concurrent oncogenic lesions may account for the activity of low-dose treatment regimens in pLGGs. Two features differentiate pLGGs from most other tumors, both for adults and pediatric patients. The first is the anecdotal observation by many practitioners that patients that have been previously responsive to a particular LGG therapy can reuse the same treatment again, often with good effect. This contrasts with most treatments, where once a tumor has seen a set of agents in a treatment and then recurred or progressed, further therapy with those same agents is ineffective. The second feature of pLGGs that differentiate them from most other tumors, including adult LGGs, is the overall excellent long-term survival of these patients. Even in the context of repeated recurrences through childhood, the majority of pediatric patients will eventually have cessation of tumor growth without the need for further therapy rather than slow transformation to progressively more malignant gliomas, as is routinely observed in adults. This effect has been especially well-identified in LGGs in patients with NF-1 and can occasionally even result in spontaneous tumor regression. A similar slowing of growth and eventual growth arrest appears to occur in sporadic pLGGs as these patients enter adulthood.

While clinical trials with a host of targeted agents for pLGGs have only recently started, it is reasonable to begin to consider how combination therapies for these kinds of agents could be developed (50). For pLGGs where the mutational heterogeneity is limited, targeting multiple pathways might be less important. If pLGGs, which are largely characterized by activation of a single pathway (RAS, RAF, TSC, FGFR1, or MYB/MYBL1), then perhaps 2 inhibitors that target the same pathway would better ensure that any signal that gets through the first blockage (say a BRAF<sup>V600E</sup> inhibitor) could be eliminated with a MEK, ERK, or mTOR inhibitor further downstream. In melanoma trials of BRAF<sup>V600E</sup>-targeted inhibitors, the addition of downstream inhibition of MEK improved the activity over either drug alone (51). Early-phase trials in adults with solid tumors are investigating combination therapy with TORC1 inhibitors (everolimus or temsirolimus) and BRAF<sup>V600E</sup> inhibitors (NCT01596140). Alternatively, dual phosphoinositide 3-kinase (PI3K)/mTOR inhibitors such as BEZ235 are being combined with the MEK1/2 inhibitor MEK162 (NCT01337765). If such combinations are tolerable, the dual activation of BRAF/MEK/ERK and mTOR pathways in aggressive pLGG provides a strong rationale for moving these, or similar drugs, into clinical trials in children.

**The challenges for the rare subtypes of pLGGs (e.g., PXA, PMA)**

With the development of improved molecular diagnosis of pLGGs, what was once considered to be a limited number of different tumor types has developed into a continuum of tumors with shared molecular defects. Although it has been suggested that the presence of KIAA/BRAF fusions may correlate with improved event-free survival (52), another study has not associated BRAF molecular alteration with outcome or identified a mutational signature in all members of a specific tumor subtype (53). Thus, it remains to be determined whether classification needs to switch from a purely immunohistochemical one to a system that prioritizes these molecular aspects. Current chemotherapy approaches have been effective in the more common forms of pLGGs such as pilocytic astrocytomas, fibrillary astrocytomas, and astrocytoma not otherwise specified. Retrospective studies are now being conducted to assess what impact the mutational pattern in these tumors had in relation to response to therapy. Although the rare subtypes of pLGGs are less well-studied, their responses appear to approximate those mentioned above in reports where they were included in chemotherapy treatment protocols.

Deciding on how to approach rare subtypes of pLGGs such as ganglioglioma, pleomorphic xanthoastrocytoma (PXA), dysembryoplastic neuroepithelial tumor (DNT), angiocentric glioma, pilomyxoid astrocytoma (PMA), and others has become less of a diagnostic issue. Rather, as we move toward identification of the molecular pathways driving these rare subtypes, we recognize that their genomic changes show patterns of overlap between each other in some, but not all, cases. The presence of the BRAF<sup>V600E</sup>...
mutation for example is identified in approximately 20% of fibrillary grade II astrocytomas but not most pilocytic astrocytomas (20). It is very common in both ganglioglioma (20) and PXAs (54) and occasionally identified in pilomyxoid astrocytomas. Because all of these tumors are potential targets for BRAFV600E inhibitors, should treatment be based on the WHO classification of the tumor subtype or on the specific molecular defect? As mentioned above, a new clinical trial of a specific BRAFV600E inhibitor is now underway and combines all pLGGs with this mutation together into a single protocol. For many of the rarer subtypes of pLGGs, not all of the molecular defects have been identified. For example, while 60% of ganglioglioma and PXAs have the BRAFV600E mutation, we do not yet know what drives the remaining 40%. Similarly, for pilomyxoid astrocytomas, some have the BRAFV600E mutation, some have the KIAA-truncated fusion of BRAF and some have neither. It is likely that to optimize therapy in this group of patients, different therapies for these different molecular subgroups of this single entity may be needed.

Conclusion
This is an exciting time in the treatment of pLGGs. Our integration of the WHO classification with molecular genotypes offers us the opportunity to tailor therapy and ideally minimize toxicity in this patient population. Whether the application of these therapies will improve on the historic PFS seen with traditional chemotherapy and result in durable complete responses is unknown. Moreover, whether biology-driven targeted therapy should be integrated with, or replace, standard upfront therapies such as carboplatin-based regimens or TPCV remains to be tested. Improvements in preclinical models of pLGGs, and clinical trials with targeted therapy that will provide some of this information, are already underway.

Authors’ Contributions

Conception and design: E.H. Raabe, M.W. Kieran, K.J. Cohen

Development of methodology: E.H. Raabe

Writing, review, and/or revision of the manuscript: E.H. Raabe, M.W. Kieran, K.J. Cohen

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M.W. Kieran

Grant Support
This study is supported by St. Baldrick’s Scholar (to E.H. Raabe), Pediatric Low-Grade Astrocytoma Foundation (to E.H. Raabe and M.W. Kieran), Andrysiak Low-Grade Glioma Scholar Award (to M.W. Kieran), and Solving Kids’ Cancer (K.J. Cohen).


New Strategies in Pediatric Gliomas: Molecular Advances in Pediatric Low-Grade Gliomas as a Model

Eric Raabe, Mark W. Kieran and Kenneth J. Cohen


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-13-0662

Cited articles
This article cites 53 articles, 20 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/19/17/4553.full#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.